Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Coating of "Self” Peptides Protects Nanoparticles from Macrophage Destruction

By BiotechDaily International staff writers
Posted on 05 Mar 2013
Print article
Image: Diagram of Macrophage Interaction: Macrophages are immune cell “border guards” that have evolved to eat all sorts of foreign microbes, but they also eat many particles that are intended for therapeutics and imaging. A “Minimal peptide ‘Passport’” attached to the particles provides recognition signals so that the particles are not eaten, thus improving delivery to diseased cells in the body (Photo courtesy of Mary Leonard, Biomedical Art & Design, University of Pennsylvania).
Image: Diagram of Macrophage Interaction: Macrophages are immune cell “border guards” that have evolved to eat all sorts of foreign microbes, but they also eat many particles that are intended for therapeutics and imaging. A “Minimal peptide ‘Passport’” attached to the particles provides recognition signals so that the particles are not eaten, thus improving delivery to diseased cells in the body (Photo courtesy of Mary Leonard, Biomedical Art & Design, University of Pennsylvania).
Nanoparticles coated with peptides derived from the human protein CD47 were protected from uptake and destruction by macrophages in a genetically engineered mouse model system.

The membrane protein CD47 is reportedly a "marker of self" in mice that impedes phagocytosis of “self” molecules by signaling through the phagocyte receptor CD172a. CD47, which is found on almost all mammalian cell membranes, binds to the SIRPa macrophage receptor in humans.

Investigators at the University of Pennsylvania (Philadelphia, USA) used computers to design the smallest peptides from human CD47 (hCD47) that could perform the same function. They then synthesized these peptides and attached them to virus-size particles for intravenous injection into mice that had been genetically engineered to express a CD172a variant compatible with hCD47.

Results published in the February 22, 2013, issue of the journal Science revealed that the coating of “self” peptides delayed macrophage-mediated clearance of the nanoparticles, which promoted persistent circulation that enhanced dye and drug delivery to tumors.

"There may be other molecules that help quell the macrophage response," said senior author Dr. Dennis Discher, professor of chemical and biomolecular engineering at the University of Pennsylvania, "but human CD47 is clearly one that says, "Do not eat me. It can be made cleanly in a machine and easily modified during synthesis in order to attach to all sorts of implanted and injected things, with the goal of fooling the body into accepting these things as self."

Related Links:

University of Pennsylvania



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.